Literature DB >> 3157445

Inhibition of protein kinase C by tamoxifen.

C A O'Brian, R M Liskamp, D H Solomon, I B Weinstein.   

Abstract

The antiestrogen drug tamoxifen inhibits rat brain protein kinase C in vitro, whether the enzyme is activated by Ca2+ and phospholipid (50% inhibitory dose, 100 microM), 12-O-tetradecanoylphorbol-13-acetate and phospholipid (50% inhibitory dose, 40 microM), or teleocidin and phospholipid. Tamoxifen does not inhibit the Ca2+- and phospholipid-independent phosphorylation of protamine sulfate by protein kinase C, indicating that the drug does not interact with the active site of the enzyme. The binding of [3H]phorbol dibutyrate to high-affinity membrane receptors of cultured mouse fibroblast cells is inhibited by tamoxifen (50% inhibitory dose, 5 microM). Our findings suggest that the growth-inhibitory and cytotoxic effects of tamoxifen, which have been observed at microM concentrations of the drug, may be in part due to its effects on protein kinase C.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3157445

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  96 in total

1.  Conventional Dose CAF Therapy versus Low Dose Adriamycin Therapy in the Treatment of Advanced Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1994-07-30       Impact factor: 4.239

Review 2.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

3.  Dehydroepiandrosterone sulfate directly activates protein kinase C-beta to increase human neutrophil superoxide generation.

Authors:  David J Radford; Keqing Wang; Joanne C McNelis; Angela E Taylor; Georg Hechenberger; Johann Hofmann; Hema Chahal; Wiebke Arlt; Janet M Lord
Journal:  Mol Endocrinol       Date:  2010-02-19

4.  Happy birthday protein kinase C: past, present and future of a superfamily.

Authors:  Fiorenzo Battaini; Daria Mochly-Rosen
Journal:  Pharmacol Res       Date:  2007-05-18       Impact factor: 7.658

5.  A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro.

Authors:  F T Vertosick; R G Selker; M S Randall; M P Kristofik; T Rehn
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Tamoxifen-induced modification of serum lipoprotein phospholipids in the cockerel.

Authors:  W C Breckenridge; C B Lazier
Journal:  Lipids       Date:  1987-07       Impact factor: 1.880

7.  Protein kinase C isoform alpha overexpression in C6 glioma cells and its role in cell proliferation.

Authors:  G H Baltuch; N P Dooley; K M Rostworowski; J G Villemure; V W Yong
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Inhibitory effects of tamoxifen and tumor necrosis factor alpha on human glioblastoma cells.

Authors:  K Iwasaki; S A Toms; G H Barnett; M L Estes; M K Gupta; B P Barna
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

Review 9.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

10.  Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells.

Authors:  Cheppail Ramachandran; Ziad Khatib; Athena Petkarou; John Fort; Hugo B Fonseca; Steven J Melnick; Enrique Escalon
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.